FDA Approves Ultragenyx's GENGLYCOS Gene Therapy as First Treatment Targeting the Underlying Cause of GSDIa

The U.S. Food and Drug Administration on August 19 granted accelerated approval to Ultragenyx Pharmaceutical's GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). The approval is the first gene therapy and fifth FDA approval overall for Ultragenyx, and the agency issued a Priority Review Voucher alongside the approval.

Why GSDIa Matters Beyond Its Rarity

GSDIa is an ultra-rare genetic metabolic disorder caused by a deficiency in the glucose-6-phosphatase enzyme, which the liver needs to release glucose into the bloodstream. The deficiency reduces the liver's ability to control glucose levels and is associated with potentially life-threatening hypoglycemia episodes and other serious complications, requiring rigorous nutritional management that involves a burdensome, around-the-clock regimen of raw cornstarch intake as an oral glucose replacement therapy. The GSDIa population is estimated at 1,500 to 2,500 patients in the U.S. and 6,000 to 8,000 worldwide in commercially accessible geographies. 「Day-to-day management of GSDIa requires a relentless regimen of raw cornstarch and strict dietary management that can be extraordinarily demanding for patients and families,」 said David Weinstein, one of the world's leading GSDIa experts. 「Even with meticulous adherence to this regimen, patients must be perfect. Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death.」

What GENGLYCOS Does

GENGLYCOS is a single-infusion adeno-associated virus (AAV) gene therapy designed to deliver a functional copy of the G6PC1 gene, which encodes the glucose-6-phosphatase enzyme, to the patient's liver. The pivotal clinical program supporting the approval enrolled patients across three studies and showed durable reductions in cornstarch dependence and improvements in metabolic control. 「The approval of GENGLYCOS fulfills our commitment to provide the first therapy that directly targets the root cause of GSDIa,」 said Eric Crombez, M.D., chief medical officer at Ultragenyx. 「The reduced reliance on cornstarch, experienced by patients in our clinical studies, demonstrates this gene therapy's ability to establish the normal breakdown of glycogen to produce glucose during fasting or episodes of metabolic stress.」

The Priority Review Voucher

Ultragenyx received a Priority Review Voucher (PRV) with the GENGLYCOS approval, per the FDA's standard mechanism for rare pediatric disease approvals. The PRV can be applied to a future Ultragenyx application to shorten the FDA review window from 10 months to 6 months, and it is also transferable — Ultragenyx has historically used PRVs strategically, applying some internally and selling others to recoup development cost. The market for transferred PRVs has historically cleared at $90 to $110 million per voucher in the secondary market, providing Ultragenyx with a near-term optionality that the company will likely disclose on its next earnings call. The PRV issuance is a signal that the FDA considers GSDIa to qualify as a rare pediatric disease even though the approval includes adults, because the genetic disease manifests from childhood.

What It Means for Patients and the Field

For GSDIa patients, GENGLYCOS is the first treatment that addresses the underlying biology rather than the cornstarch-based symptom-management protocol that has been the standard of care for decades. The drug is administered as a single intravenous infusion, with a list price that Ultragenyx will disclose in the coming weeks but that is expected to be consistent with other ultra-rare-disease gene therapies at $1.5 million to $3.5 million per patient. Ultragenyx has committed to a comprehensive patient-assistance program that includes co-pay support for commercially insured patients and free drug for uninsured patients who meet income criteria. For the broader glycogen-storage-disease field, the GENGLYCOS approval validates liver-directed AAV gene therapy as a delivery modality for metabolic disorders and opens the door to additional programs in GSDIb, GSDIII and Pompe disease.

What to Watch Through Year-End

Three checkpoints follow. Ultragenyx will host a conference call on August 19 at 6:00 p.m. Eastern Time to discuss the approval and the company's launch plans. The first commercial administration is expected in Q4 2026 at qualified treatment centers. And the broader gene-therapy-pipeline implications will begin to clarify in October, when Ultragenyx's Q3 earnings disclosure provides the first quantitative detail on commercial uptake, payer-coverage posture and pricing-realization data.